In 2026, Novo Nordisk’s patent on semaglutide will expire in several countries, including India and China. Generic-drug makers are poised to flood these markets with inexpensive products. Industry ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback